Shandong Weigao Blood (603014) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Shandong Weigao Blood stock ¥11.89, price ¥34.86, that is 65.9% below the price, quality 52 out of 100. Rating: strongly overvalued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
18‑month range ¥29.06 – ¥45.74 · fair‑value band ¥9.36 – ¥15.01 · the ¥34.86 price screens above the ¥11.89 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Shandong Weigao Blood in your weekly email
Every Wednesday you see whether Shandong Weigao Blood is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shandong Weigao Blood Purification Products Co., Ltd. engages in the research and development, production, and sale of blood purification medical products in China.
Show moreShow less
It offers dialyzers; dialysis machines; hemodialysis tubing, products, and machines; peritoneal dialysis products; dialysis supporting products, such as hemoperfusion devices, dialysis powder and liquid, puncture needles, and iodine caps for peritoneal dialysis.
The company was founded in 2004 and is based in Weihai, China.
Stock analysis
Shandong Weigao Blood (603014) currently trades at ¥34.86, while our model-based Fair Value estimate is ¥11.89, 66% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ¥14.86 per share, and 1 of the 25 models we run sit above the ¥34.86 price.
Bear case: the Dividend Discount group reads lowest at ¥1.20, and 24 of the 25 models stay below the price. Data coverage for this calculation is high.
Scenario range: ¥9.36 (bear) to ¥15.01 (bull), the price of ¥34.86 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Shandong Weigao Blood reported revenue of 3.8B CNY in FY2025 versus 2.9B CNY in FY2021, a compound +6.7%/yr. Reported net income was 482M CNY in FY2025, compounding +16.7%/yr from FY2021.
Key figures
Market cap 24.1B CNY (≈ $3.6B) Mid · P/E ratio 29.3 · P/S ratio 3.84 · EPS (TTM) ¥1.19 · Dividend yield 1.6% · Net margin 13.1% · Return on equity 7.0% · Return on assets (EBIT) 9.9% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (low confidence).
What moves the price
The share trades about 23% below its 52-week high and 20% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −66%, 603014 screens richer than that median.
Fair Value models
Bear¥9.36Fair Value ¥11.89Bull¥15.01
Price ¥34.86 · Downside -65.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.5291 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF¥10.85¥14.13¥18.3677
Growth DCF¥11.01¥13.99¥17.6674
Residual Income¥7.98¥8.21¥8.8473
All 25 models by family
DCF Models
FCF DCF¥10.85¥14.13¥18.3677
Owner Earnings¥11.10¥14.47¥18.8372
5Y Revenue Exit¥9.81¥13.35¥17.6868
5Y EBITDA Exit¥12.10¥17.44¥23.4270
5Y P/E Exit¥11.72¥16.77¥21.8166
10Y Revenue Exit¥9.96¥13.08¥16.9063
10Y EBITDA Exit¥11.50¥15.68¥20.8464
10Y P/E Exit¥11.27¥15.25¥19.7360
Earnings-Based
Graham-Dodd¥4.72¥11.50¥14.8762
PEG = 1.0¥2.05¥2.93¥3.8155
EPV¥7.60¥8.36¥9.0168
Dividend Discount
Gordon GGM¥0.7700¥1.28¥1.8465
DDM Multi-Stage¥0.7700¥1.11¥1.4464
Multiples
P/E Multiple¥11.45¥15.27¥19.0963
P/S Multiple¥8.85¥11.80¥14.7558
P/B Multiple¥33.17¥44.23¥55.2855
EV/EBIT¥9.72¥13.13¥16.5363
EV/EBITDA¥11.67¥15.73¥19.7864
EV/Revenue¥6.79¥9.92¥13.0551
Asset-Based
NCAV (Graham)¥3.02¥4.58¥5.7352
Growth DCF
Growth DCF¥11.01¥13.99¥17.6674
Rev-Margin DCF¥9.81¥13.46¥17.4468
Economic Profit
Residual Income¥7.98¥8.21¥8.8473
ROIC Compounder¥7.60¥8.36¥9.0167
Growth Earnings
Growth-Adj P/E¥8.73¥12.47¥16.2165
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.69/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+4.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.2%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+10.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+9.2%
Dividend (yield on the price)1.6%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 15%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +9.9% a year for the price and +6.3% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks
Beats the industry median on 4/13 measures
Overall it trails its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside−65.9% · Bottom 25%
Profitability
Return on equity (12 months)7.0% · Above median
Return on assets5.6% · Above median
Net margin (12 months)13.1% · Above median
Operating margin (12 months)12.2% · Above median
Growth and dividend
Revenue growth (quarter YoY)−1.7% · Bottom 25%
Dividend yield (12 months)1.6% · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)29.3× · Pricier than median
P/B3.39× · Priciest 25%
P/S (12 months)6.41× · Priciest 25%
Price / free cash flow (fiscal year)38.0× · Pricier than median
EV/EBITDA28.2× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 6
FUTURE (revenue growth)0· sector 35
PAST (return on equity)28· sector 17
HEALTH (low debt)0· sector 98
DIVIDEND (yield)33· sector 34
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Shandong Weigao Blood (603014) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of ¥11.89 versus a price of ¥34.86, about 66% lower (overvalued).
What is the fair value of 603014?
Our model-based fair value for Shandong Weigao Blood is ¥11.89 (as of Nov 6, 2026), built from audited fundamentals. The current price: ¥34.86.
What is the quality score of 603014?
Shandong Weigao Blood has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shandong Weigao Blood (603014)?
Our model-based price target is the fair value of ¥11.89 (as of Nov 6, 2026) from 25 valuation models. Cautious scenario ¥9.36, optimistic scenario ¥15.01. It is a calculation from audited fundamentals, not an analyst target.
What is the Shandong Weigao Blood stock forecast for 2026?
Our models put fair value at ¥11.89, about 66% lower versus a price of ¥34.86 (overvalued). Cautious scenario ¥9.36, optimistic scenario ¥15.01. The calculation is refreshed regularly with new filings.
What is the revenue of Shandong Weigao Blood (603014)?
Shandong Weigao Blood reported trailing-twelve-month revenue of about 3.8B CNY (latest available figure, as of Nov 6, 2026).
Does Shandong Weigao Blood pay a dividend?
Shandong Weigao Blood currently shows a dividend yield of 1.64% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Shandong Weigao Blood (603014) and when is the ex-dividend date?
Shandong Weigao Blood pays a dividend of ¥0.571 per share a year, a dividend yield of 1.6%. The last ex-dividend date was Sep 14, 2026. The payout ratio is 48.0% of earnings. Free cash flow covers the dividend 1.60 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Shandong Weigao Blood (603014)?
For today's price to be fair in a discounted-cash-flow model, Shandong Weigao Blood would have to grow free cash flow by +11.7 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +6.7 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of 603014 use?
Our models discount Shandong Weigao Blood at 10.4 %: a base by market capitalisation (mid), country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Shandong Weigao Blood that is +11.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Shandong Weigao Blood (603014) delivered so far?
Over the past 4 years revenue at Shandong Weigao Blood grew +6.7 % a year. The price currently implies free-cash-flow growth of +11.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Shandong Weigao Blood (603014) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into Shandong Weigao Blood (+11.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Shandong Weigao Blood (603014)?
The free-cash-flow yield on the price is 4.35 %: that much free cash flow Shandong Weigao Blood produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Shandong Weigao Blood (603014)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shandong Weigao Blood it is ¥11.89 per share (as of Nov 6, 2026), against a price of ¥34.86. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Shandong Weigao Blood stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 603014 trades above its calculated fair value: price ¥34.86, fair value ¥11.89, a gap of about −66% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 603014?
No. The price is what the market pays today (¥34.86); the fair value is what the company's own numbers justify (¥11.89). For Shandong Weigao Blood the two are ¥22.97 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shandong Weigao Blood worth?
The market values Shandong Weigao Blood at about 24.1B CNY (market capitalisation, as of Nov 6, 2026). Per share that is ¥34.86; our models calculate a fair value of ¥11.89 per share.
What do the bullish and bearish scenarios say about 603014?
Our models span a range for Shandong Weigao Blood: cautious scenario ¥9.36, base ¥11.89, optimistic ¥15.01 per share (as of Nov 6, 2026, price ¥34.86). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 603014?
Shandong Weigao Blood trades at a price-to-earnings ratio of 29.3 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥11.89 is built from several models across several years. Other multiples: P/B 3.4, P/S 6.4, EV/EBITDA 28.2.
How solid is the balance sheet of Shandong Weigao Blood (603014)?
Balance-sheet figures for Shandong Weigao Blood (as of Nov 6, 2026): return on equity 7.0%. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is 603014 from its 52-week high?
Shandong Weigao Blood trades at ¥34.86, about 23% below its 52-week high of ¥45.12 and 20% above the low of ¥29.06 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥11.89 is for.
Which stocks are comparable to Shandong Weigao Blood?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shandong Weigao Blood stock attractive at the current price?
The data as of Nov 6, 2026: price ¥34.86, calculated fair value ¥11.89 (−66%), Quality Score 52/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 603014 calculated?
We run Shandong Weigao Blood through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥11.89 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Shandong Weigao Blood itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shandong Weigao Blood (603014)?
The closing price on Nov 6, 2026 was ¥34.86. Our model-based fair value is ¥11.89, about 66% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shandong Weigao Blood right now?
The price sits above even our optimistic bull case (¥15.01). The favourable scenario is already priced in. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Shandong Weigao Blood
How large is the market capitalisation of Shandong Weigao Blood (603014)?
The market capitalisation of Shandong Weigao Blood is 24.1B CNY (≈ $3.6B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shandong Weigao Blood (603014)?
The price-to-sales ratio of Shandong Weigao Blood is 3.84 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shandong Weigao Blood (603014)?
Earnings per share at Shandong Weigao Blood are ¥1.19 (price ÷ EPS = P/E 29.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shandong Weigao Blood (603014)?
The dividend yield of Shandong Weigao Blood is 1.6% (payout 48.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shandong Weigao Blood (603014)?
The net margin of Shandong Weigao Blood is 13.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shandong Weigao Blood (603014)?
The return on equity (ROE) of Shandong Weigao Blood is 7.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shandong Weigao Blood (603014)?
On an EBIT basis the return on assets of Shandong Weigao Blood is 9.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shandong Weigao Blood (603014)?
The operating margin of Shandong Weigao Blood is 12.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shandong Weigao Blood (603014)?
Revenue at Shandong Weigao Blood is growing −1.7% versus a year earlier (3y avg +3.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shandong Weigao Blood (603014)?
Earnings per share at Shandong Weigao Blood are growing −3.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Shandong Weigao Blood (603014) carry?
The net debt of Shandong Weigao Blood is 349M CNY (fiscal year 2021, ≈ 0.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Shandong Weigao Blood in the live analysis
One click puts Shandong Weigao Blood on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026